Precision AQ - Investor Relations & External Communications’ Post

Our week starts with a promising piece of news for the #DINcommunity #CIDP #dysimmuneinflammatoryneuropathies #cureDINs #treatDINs #peoplelivingwithDINs #DINpeople #clinicaltrials #medicalresearch

Ataxia Telangiectasia (AT) is a rare, progressive disease that typically presents in early childhood and is characterized by neurological and immunological symptoms. Currently, there is no cure or FDA-approved treatment to slow the progression of AT, with the average life expectancy being around 25 years for those diagnosed in childhood. Find out more about ChromaDex's planned development of NRC for the treatment of AT here: https://bit.ly/4cbamFA

Next important pathway in inflammatory bowel disease and beyond, lets get the clinical proof points

Here is a story of a #pharmacist fighting for her kids battling #cysticfibrosis, a disease that impacts the #lungs, and #liver causing #CFLD, cystic fibrosis #liverdisease, #pancreas causing #CFRD, cystic fibrosis-related #diabetes, gut-causing #leakygut, and #dysbiosis. How to diagnose, and treat cystic fibrosis, the #lifeexpectancy in cystic fibrosis, how #pharmacogenomic and #nutrigenomic testing helps and the #functionalmedicine approach to manage #CF. Thank you Julie Wharam, PharmD, CPGx for sharing this story with Healthieyoo! https://lnkd.in/gxyRBpDM

A Phase 3 #clinicaltrial studying the effects of #Ozempic on Type 2 diabetes patients with chronic kidney disease? And, the trial was run during Covid? You have to check this out. https://lnkd.in/gvBmT5wV

More analysis and reporting from the ground breaking SONAR program we are working on in CKD and T2 Diabetes

In the lead up to #ADA2023, #eHCPs discussed a wide variety of treatments and trials related to diabetic kidney disease. DAPA-CKD trial, which looks at #dapagliflozin in preventing adverse DKD outcomes, was the most widely spoken about. Learn more here https://bit.ly/3LIzqsW #diabetes #diabeteschat

#quiztime #rarediseases Rare Disease Quiz: https://lnkd.in/euT74Xc8 I got 22/30. How many did you get? Post in comments. The third panel discussion at the upcoming US Connect, 25–28 February, is 'Are We There Yet? Rare Disease Clinical Trials'. While we may not cover the questions in the quiz, we do intend to address some very interesting ideas: ↳ Global collaboration between researchers, pharmaceuticals and regulatory authorities ↳ Understanding the unique challenges of rare disease clinical trials ↳ Innovations in statistical methodologies that support small population studies Register for the US Connect: https://lnkd.in/ehvjeNNe Full Agenda: https://lnkd.in/eGqjTqYv Panel Discussion on Rare Disease Clinical Trials on 28Feb2024. Meet the Panelists - Sheeba Arnold, Todd Case, Berber Snoeijer, Sophia Zilber 🌺, Michael Litzsinger

Important article in Pharmafile.com by our client Dr Dan Williams at SynaptixBio Ltd. Dan considers the ongoing challenges facing rare disease patients, and discusses developments in the search for therapies. Many thanks to Betsy Goodfellow. The full article is here: https://lnkd.in/e_58twVs.

Looking forward to having specific effective therapy for Sjogren:s Disease. It is over 90 years since it was first clearly defined as a systemic autoimmune rheumatic condition. by Dr. Henrik Sjogren...and yet we struggle for effective treatment.